作为唯一一家亚洲上市早筛企业，Mirxes觅瑞是一家以新加坡为总部的RNA生物科技公司，深耕东 南亚及东亚市场，致力于开发及商业化针对癌症及其他疾病早期筛查的精准、无创、可负担的血液 miRNA检测，是全球首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。不仅如此， Mirxes觅瑞的产品管线丰富，已形成商业化落地、临床推进、临床前研发的梯队布局。除核心胃癌 筛查产品外，公司肺癌、结直肠癌、乳腺癌等单癌种早筛产品均处于有序研发推进阶段，其中结直肠 癌筛查产品有望于近期上市。同时，公司前瞻性布局CADENCE多癌种多组学检测项目，全面覆盖癌 症早筛领域的多元化市场需求。凭借丰富且梯度化的产品管线布局，公司未来增长空间巨大。核心产 品觅小卫®成功获得中国国家药品监督管理局第三类医疗器械注册证，这一里程碑式的成果充分印证 公司技术路径与商业化逻辑正稳步兑现。乘着行业发展的东风，依托自身扎实的综合实力与持续兑现 的成长验证，觅瑞必将在精准医疗的浪潮中稳步前行，不断开拓创新，擘画属于自身的伟大前程，为 全球癌症防控事业创造更深远的价值。 近期，Mirxes觅瑞发布公告，与晶泰科技正式签署战略合作谅解备忘录，瞄准亚 ...

Group 1: Industry Trends and Innovations - The "2025 Fifth China Health Industry Development and Rehabilitation Service Conference" was held in Beijing, focusing on integrating resources and exploring development paths in the health industry [1] - The conference featured discussions on cutting-edge topics such as innovative drugs, brain-machine interfaces, AI in healthcare, and the transformation of traditional Chinese medicine [1] - A series of innovative case studies were presented, showcasing advancements in areas like ESG, biotechnology, and AI healthcare, reflecting the vitality and innovation in the health sector [1] Group 2: Company Highlights - Gan Li Pharmaceutical is the first company in China to master the industrial production of recombinant insulin analogs, recently achieving significant milestones with its insulin injection and a commercial agreement for a GLP-1 receptor agonist [2] - Shengxiang Bio focuses on integrated diagnostic and therapeutic solutions, having developed over 1,000 products and served more than 30 billion tests globally, emphasizing its commitment to making life sciences accessible [3] - Nanjing Xinbai has established a dual-driven model in cell therapy and clinical transformation, with significant advancements in immunotherapy for prostate cancer and a leading position in umbilical cord blood storage [4][5] - Mirxes has developed a non-invasive gastric cancer screening solution, filling a technological gap in China and demonstrating significant clinical applicability and commercial potential [9] - Ruixi Bio specializes in micro-ecological medical solutions, having built a comprehensive database and developed a novel theory for precision medical interventions in chronic diseases [12][13]